Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Long-Term Debt Repayments (2021 - 2022)

PharmaCyte Biotech (PMCB) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $50805.0 as the latest value for Q2 2022.

  • On a quarterly basis, Long-Term Debt Repayments rose 200.0% to $50805.0 in Q2 2022 year-over-year; TTM through Apr 2022 was $38169.0, a 402.07% increase, with the full-year FY2022 number at $50805.0, down 18.63% from a year prior.
  • Long-Term Debt Repayments was $50805.0 for Q2 2022 at PharmaCyte Biotech, up from -$50805.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $50805.0 in Q2 2022 to a low of -$50805.0 in Q2 2021.